Umiddelbart forekommer det indlysende, at patienter, der desuden har fået behandling med kurativt sigte, ved tillægsbehandling med bicalutamid ikke opnår så stor en forbedring af prognosen som andre patienter.
It seems intuitive that for good prognosis patients who have also received treatment of curative intent, the addition of bicalutamide might confer less benefit than in other patients.